Evidence map›Paper›PMID 42432424›Full record

ArticleJournal of the American Heart Association2026

Plasma Apolipoprotein E Levels and Adverse Clinical Outcomes After Ischemic Stroke.

Lingxiang Ye, Shiliang Xia, Quan Yu, Beiping Song, Yang Liu, Lulu Sun, Xueyu Mao, Xuechun Wu, Min Chu, Huicong Niu and 6 more

Abstract read
In one paragraph

Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Lingxiang Ye *Department of Epidemiology, The Affiliated Guangji Hospital of Soochow University, School of Public Health Suzhou Medical College of Soochow University Suzhou Jiangsu China.ORCID 0009-0005-8769-9487
Shiliang Xia *Department of Neurology, Minhang Hospital Fudan University Shanghai China.
Quan Yu *Department of Epidemiology, The Affiliated Guangji Hospital of Soochow University, School of Public Health Suzhou Medical College of Soochow University Suzhou Jiangsu China.
Beiping SongDepartment of Epidemiology, The Affiliated Guangji Hospital of Soochow University, School of Public Health Suzhou Medical College of Soochow University Suzhou Jiangsu China.
Yang LiuDepartment of Neurology, Minhang Hospital Fudan University Shanghai China.ORCID 0000-0001-5939-572X
Lulu SunDepartment of Epidemiology, The Affiliated Guangji Hospital of Soochow University, School of Public Health Suzhou Medical College of Soochow University Suzhou Jiangsu China.
Xueyu MaoDepartment of Neurology, Minhang Hospital Fudan University Shanghai China.ORCID 0000-0001-6143-197X
Xuechun WuDepartment of Neurology, Minhang Hospital Fudan University Shanghai China.
Min ChuDepartment of Neurology, Minhang Hospital Fudan University Shanghai China.ORCID 0000-0003-2973-8386
Huicong NiuDepartment of Neurology, Minhang Hospital Fudan University Shanghai China.ORCID 0000-0001-9112-8883
Daoxia GuoSchool of Nursing Suzhou Medical College of Soochow University Suzhou Jiangsu China.ORCID 0000-0002-4537-0705
Mengyao ShiDepartment of Epidemiology, The Affiliated Guangji Hospital of Soochow University, School of Public Health Suzhou Medical College of Soochow University Suzhou Jiangsu China.
Qi FangDepartment of Neurology The First Affiliated Hospital of Soochow University Suzhou Jiangsu China.ORCID 0000-0002-9762-2687
Jing YuanState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences University of Macau Macao SAR China.
Zhengbao ZhuDepartment of Epidemiology, The Affiliated Guangji Hospital of Soochow University, School of Public Health Suzhou Medical College of Soochow University Suzhou Jiangsu China.ORCID 0000-0001-5500-0014
Jing ZhaoDepartment of Neurology, Minhang Hospital Fudan University Shanghai China.ORCID 0000-0001-5197-9181

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundApolipoprotein E (ApoE) is implicated in the development of cerebrovascular diseases, but its association with the prognosis of ischemic stroke remains unclear. We aimed to explore the associations between plasma ApoE levels and adverse clinical outcomes after ischemic stroke in a prognostic cohort study.

methodWe measured plasma ApoE levels among 5410 patients with ischemic stroke from the Minhang Stroke Cohort study. The primary outcome was the composite outcome of death and major disability (modified Rankin Scale score=3-6) at 3 months after stroke onset. Secondary outcomes included major disability, death, and the ordered 7-level categorical score of the modified Rankin Scale.

resultsIn the prognostic cohort study, the multivariable adjusted odds ratio associated with the highest quartile of plasma ApoE levels was 1.37 (95% CI=1.10-1.70;

conclusionsHigh plasma ApoE levels were independently associated with increased risk of adverse outcomes among patients with ischemic stroke, suggesting that plasma ApoE might be implicated in the prognosis of ischemic stroke.

Indexed as

Apolipoproteins EBrain IschemiaIschemic StrokeStrokeAgedBiomarkersChinaDisability EvaluationFemaleHumansMaleMiddle AgedMultivariate AnalysisOdds RatioPrognosisRisk FactorsApoE protein, humanApolipoproteins EBiomarkersapolipoprotein Ebiomarkerischemic strokeprognosisrisk factor

Identifiers

PMID42432424
PMCPMC13477352

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.